SCHEMBL3989446

SCHEMBL3989446

O=C1CCc2cc(-c3ccc4ccccc4c3)ccc21

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 6/20 0.60
CYP1A2 P05177 2/20 0.56
CYP11B1 P15538 1/20 0.56
CYP11B2 P19099 1/20 0.56
GSTP1 P09211 1/20 0.52
GRM5 P41594 1/20 0.49
CASP1 P29466 1/20 0.49
CASP7 P55210 1/20 0.49
HSD17B10 Q99714 1/20 0.49
PARP10 Q53GL7 1/20 0.44
PARP11 Q9NR21 1/20 0.44
HDAC4 P56524 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
PGR P06401 1/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
CYP2C9 P11712 1/20 0.43
HPGD P15428 1/20 0.43
CYP2C19 P33261 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20381783 0.89 HSD17B1 (0.53) HSD17B1CYP1A2CYP11B1CYP11B2GSTP1
SCHEMBL12762119 0.87 CYP1A2 (0.49) HSD17B1CYP1A2CYP11B1CYP11B2GSTP1
SCHEMBL28655414 0.85 HSD17B1 (0.78) HSD17B1CYP1A2CYP11B1CYP11B2GRM5
SCHEMBL1745161 0.84 HSD17B1 (0.71) HSD17B1CYP1A2CYP11B1CYP11B2GRM5
SCHEMBL4195204 0.81 GSTP1 (0.50) HSD17B1CYP1A2CYP11B1CYP11B2GSTP1
SCHEMBL3989676 0.79 HSD17B1 (0.51) HSD17B1CYP1A2CYP11B1CYP11B2GRM5
SCHEMBL3994786 0.79 HSD17B1 (0.59) HSD17B1CYP1A2CYP11B1CYP11B2GSTP1
Dimethylamine SCHEMBL3994802 0.78 HSD17B1 (0.63) HSD17B1CYP1A2CYP11B1CYP11B2GRM5
SCHEMBL6940637 0.77 CASP1 (0.52) HSD17B1CYP1A2CYP11B1CYP11B2GRM5
SCHEMBL30402712 0.77 CASP1 (0.52) HSD17B1CYP1A2CYP11B1CYP11B2GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7485655-B2 2-Aminothiazole allosteric enhancers of A1 adenosine receptors UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2009-02-03 US disclosed
EP-1583530-A4 2-AMINOTHIAZOLE ALLOSTERIC ENHANCERS OF A1-ADENOSINE RECEPTORS UNIV VIRGINIA (US) 2008-07-23 EP disclosed
EP-1583530-A1 2-AMINOTHIAZOLE ALLOSTERIC ENHANCERS OF A1-ADENOSINE RECEPTORS UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2005-10-12 EP disclosed
US-20050027125-A1 2-Aminothiazole allosteric enhancers of a ?1? adenosine receptors NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2005-02-03 US disclosed
WO-2003061655-A1 2-AMINOTHIAZOLE ALLOSTERIC ENHANCERS OF A1 ADENOSINE RECEPTORS UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2003-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050027125-A1 2-Aminothiazole allosteric enhancers of a ?1? adenosine receptors ADORA1, ADORA2A, ADORA2B HSD17B1 4023/4885CYP1A2 2684/4885CYP11B1 1981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.